This article is more than 5 years old. Information may no longer be current.
Study: Osteogenic protein-1 not as effective as iliac crest autograft for posterolateral fusion
Click Here to Manage Email Alerts
Results from a level 1 trial showed that compared with autologous iliac crest bone, osteogenic protein-1 with a collagen carrier was not as effective for achieving fusion in instrumented posterolateral lumbar fusion surgery.
Researchers identified 119 patients who underwent a single-level, instrumented posterolateral fusion of the lumbar spine for degenerative or isthmic spondylolisthesis at nine centers in four countries. Investigators assessed overall success for 57 patients who received osteogenic protein-1 (OP-1; Stryker) and 56 patients received autologous bone graft from the iliac crest combined with local bone. Success overall at 1 year, defined as clinical success and evidence of fusion on CT scans, was the primary outcome. The Oswestry Disability Index was used at all clinical follow-ups at 6 weeks, 3 months, 6 months and 12 months.
Results showed the overall success rate was 40% in patients treated with OP-1 and 54% in patients treated with autografts. Investigators noted the difference in overall success rates was due to a lower rate of fusion seen on CT scans for patients treated with OP-1.
According to researchers, 23 adverse events were seen in the OP-1 group compared with 29 events in patients treated with iliac crest autografts; however, none of the adverse events were directly related to OP-1 use. ‒ by Monica Jaramillo
Disclosures: Delawi reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts